Amiel Gross currently serves as Head of Legal at the Center for Breakthrough Medicines in Philadelphia, focusing on building and managing their legal function. He is responsible for ensuring the business strategies and policies are aligned with all risks taken into consideration. Counseling executives and senior management, negotiating complex commercial transactions, facilitating strategic alliances, supporting a range of legal issues arising during highly-regulated biotechnology business operations - these topics highlight his work as an attorney who specializes in cell & gene therapy manufacturing. This professional oversight responsibility and hands-on experience across array of subject matters. These subjects include licensing deals, master services agreements, procurement contracts, intellectual property, corporate affairs, sponsored R&D collaborations, FDA regulatory and compliance, litigation, labor and employment, cybersecurity and privacy. Amiel Gross has studied International Law at the Queen Mary University of London. He holds a Bachelor of Arts Degree from the Southwestern University and a Doctor of Law Degree from The University of Texas School of Law. His skills include general corporate counsel, life science industry, biotechnology, industry knowledge, pharmaceutical law, biopharmaceuticals, corporate law, licensing, regulatory compliance. He is also highly experienced at business transactions, commercial contracts, CDMO, CGT, cell and gene therapy.